Mereo BioPharma Group plc

NASDAQ (USD): Mereo BioPharma Group plc (MREO)

Last Price

2.87

Today's Change

-0.01 (0.34%)

Day's Change

2.84 - 2.97

Trading Volume

901,941

Overview

Market Cap

444 Million

Shares Outstanding

154 Million

Avg Volume

1,027,327

Avg Price (50 Days)

3.33

Avg Price (200 Days)

3.76

PE Ratio

-9.57

EPS

-0.30

Earnings Announcement

26-Mar-2025

Previous Close

2.88

Open

2.95

Day's Range

2.84 - 2.97

Year Range

2.525 - 5.02

Trading Volume

901,941

Price Change Highlight

1 Day Change

-0.35%

5 Day Change

-7.72%

1 Month Change

-5.28%

3 Month Change

-18.70%

6 Month Change

-29.66%

Ytd Change

-16.08%

1 Year Change

-22.22%

3 Year Change

111.03%

5 Year Change

75.29%

10 Year Change

-55.85%

Max Change

-55.85%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment